Zura Bio Limited $ZURA Stock Holdings Boosted by Suvretta Capital Management LLC

Suvretta Capital Management LLC grew its position in shares of Zura Bio Limited (NASDAQ:ZURA) by 12.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 5,472,891 shares of the company’s stock after purchasing an additional 611,952 shares during the quarter. Suvretta Capital Management LLC owned 8.42% of Zura Bio worth $23,698,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Forefront Wealth Partners LLC acquired a new stake in shares of Zura Bio in the third quarter valued at $93,000. Savant Capital LLC grew its holdings in Zura Bio by 190.4% during the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after acquiring an additional 21,249 shares during the period. Bank of America Corp DE raised its position in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares in the last quarter. AQR Capital Management LLC bought a new stake in Zura Bio in the first quarter worth about $72,000. Finally, Jane Street Group LLC acquired a new stake in Zura Bio in the 2nd quarter valued at about $113,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Trading Down 9.1%

ZURA stock opened at $6.17 on Friday. Zura Bio Limited has a one year low of $0.97 and a one year high of $7.44. The firm has a 50-day moving average of $6.07 and a two-hundred day moving average of $4.39. The firm has a market capitalization of $401.17 million, a PE ratio of -9.49 and a beta of 0.18.

Insider Activity

In other news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of Zura Bio stock in a transaction that occurred on Thursday, February 26th. The stock was acquired at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the transaction, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. The trade was a 43.93% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 14.23% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ZURA shares. Leerink Partners raised shares of Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. Wall Street Zen lowered shares of Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Wedbush began coverage on shares of Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. Finally, Chardan Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Zura Bio currently has an average rating of “Moderate Buy” and a consensus price target of $11.60.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.